{'fraction_non_alphanumeric': 0.025110782865583457, 'fraction_numerical': 0.048005908419497784, 'mean_word_length': 5.159090909090909, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Expression and clinical significance of S100 calcium binding protein A2 in lung cancer

S100 family of calcium-binding proteins plays a significant role in the process of many kinds of tumor, including lung cancer, which is the most popular malignancy worldwide. As an important member of this family,S100 calcium binding protein A2 (S100A2) has been confirmed to be associated with many biological processes, and abnormal-expressed S100A2 was observed in NSCLC. However, the S100A2status in lung cancer is still controversial and the expression of S100A2 has not been analyzed in some histological subtypes such as SCLC and Atypical carcinoid. In this study, we evaluated the pattern and distribution of S100A2 in 69 cases of lung cancer including five histological types (27 Adeno carcinma, 26 Squamous cell carcinoma,7 Small cell carcinoma, 3 Large cell carcinoma, 6 Atypical carcinoid) and 20 cases of paired adjacent normal lung tissues by means of immunohistochemistry. Compared with the normal lung tissues (0/20), S100A2 experienced a dramatically upward trend of positive expression, with a positive rate of 38/69( P P = 0.018). Our immune-context results demonstrate the association between high S100A2 expression and NSCLC at the tissues level, and S100A2 may serve as an effective biomarker for the diagnosis and prognosis of NSCLC in future.